Gene Variations and Breast Cancer Risk
Author Information
Author(s): Khedhaier Achraf, Hassen Elham, Bouaouina Noureddine, Gabbouj Sallouha, Ahmed Slim Ben, Chouchane Lotfi
Primary Institution: Laboratoire d'Immuno-Oncologie Moleculaire, Faculté de Médecine de Monastir, Tunisia
Hypothesis
This study investigates the susceptibility and prognostic implications of certain gene polymorphisms in breast carcinoma patients.
Conclusion
Polymorphisms of some xenobiotic metabolizing enzyme genes may predict the onset of breast carcinoma as well as survival after treatment.
Supporting Evidence
- The mEH (C/C) mutant and the NAT2 slow acetylator genotypes were significantly associated with breast carcinoma risk.
- CYP2D6 (G/G) wild type was associated with breast carcinoma risk only in postmenopausal patients.
- Significant differences in overall survival were found with the mEH gene polymorphisms.
- The NAT2 intermediate acetylator genotype was associated with decreased disease-free survival in axillary lymph node-negative patients.
Takeaway
Some genes can change how likely someone is to get breast cancer and how well they do after treatment.
Methodology
The study used polymerase chain reaction and restriction enzyme digestion to analyze gene variations in 560 subjects.
Participant Demographics
560 unrelated subjects (246 controls and 314 patients) from Tunisia, with a mean age of 52 for patients and 41 for controls.
Statistical Information
P-Value
p = 0.02; p = 0.01; p = 0.006; p = 0.04; p = 0.03; p = 0.001
Confidence Interval
95% CI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website